PIK3CA Exon 20 Mutation is Independently Associated with a Poor Prognosis in Breast Cancer Patients

BACKGROUND: Pyruvate kinase M2 (PKM2) was overexpressed in many cancers, and high PKM2 expression was related with poor prognosis and chemoresistance. OBJECTIVE: We investigated the expression of PKM2 in breast cancer and analyzed the relation of PKM2 expression with chemotherapy resistance to the neoadjuvant chemotherapy (NAC). We also investigated whether PKM2 could reverse chemoresistance in breast cancer cells in vitro and in vivo. METHODS: Immunohistochemistry (IHC) was performed in 130 surgical resected breast cancer tissues. 78 core needle biopsies were collected from breast cancer patients before neoadjuvant chemotherapy. The relation of PKM2 expression and multi-drug resistance to NAC was compared. The effect of PKM2 silencing or overexpression on Doxorubicin (DOX) sensitivity in the MCF-7 cells in vitro and in vivo was compared. RESULTS: PKM2 was intensively expressed in breast cancer tissues compared to adjacent normal tissues. In addition, high expression of PKM2 was associated with poor prognosis in breast cancer patients. The NAC patients with high PKM2 expression had short survival. PKM2 was an independent prognostic predictor for surgical resected breast cancer and NAC patients. High PKM2 expression was correlated with neoadjuvant treatment resistance. High PKM2 expression significantly distinguished chemoresistant patients from chemosensitive patients. In vitro and in vivo knockdown of PKM2 expression decreases the resistance to DOX in breast cancer cells in vitro and tumors in vivo. CONCLUSION: PKM2 expression was associated with chemoresistance of breast cancers, and could be used to predict the chemosensitivity. Furthermore, targeting PKM2 could reverse chemoresistance, which provides an effective treatment methods for patients with breast cancer.

Download Full-text

10-year follow-up update of French adjuvant study group 05 trial: FEC 100 regimen remains superior to FEC 50 in adjuvant chemotherapy of poor prognosis, node-positive, early breast cancer patients

The Breast ◽

10.1016/s0960-9776(03)80112-1 ◽

2003 ◽

Vol 12 ◽

pp. S35

Author(s):

V. Servent ◽

J. Bonneterre ◽

H. Roché ◽

P. Kerbrat ◽

A. Brémond ◽

...

Keyword(s):

Breast Cancer ◽

Adjuvant Chemotherapy ◽

Cancer Patients ◽

Early Breast Cancer ◽

Poor Prognosis ◽

Study Group ◽

Breast Cancer Patients ◽

Node Positive

Download Full-text

Abnormal gene expression leads to poor prognosis in breast cancer patients in Bihar

Comparative Clinical Pathology ◽

10.1007/s00580-016-2261-x ◽

2016 ◽

Vol 25 (4) ◽

pp. 763-768

Author(s):

Aseem Kumar Anshu ◽

Akhileshwari Nath ◽

Prinyanka ◽

Neha Sinha ◽

Priyanka Sinha ◽

...

Keyword(s):

Breast Cancer ◽

Gene Expression ◽

Cancer Patients ◽

Poor Prognosis ◽

Breast Cancer Patients

Download Full-text

Prediction of Poor Prognosis in Breast Cancer Patients Based on MicroRNA-21 Expression: A Meta-Analysis

PLoS ONE ◽

10.1371/journal.pone.0118647 ◽

2015 ◽

Vol 10 (2) ◽

pp. e0118647 ◽

Cited By ~ 16

Author(s):

Yanyan Wang ◽

Yujie Zhang ◽

Chi Pan ◽

Feixia Ma ◽

Suzhan Zhang

Keyword(s):

Breast Cancer ◽

Cancer Patients ◽

Poor Prognosis ◽

Meta Analysis ◽

Breast Cancer Patients

Download Full-text

High Moesin Expression Is a Predictor of Poor Prognosis of Breast Cancer: Evidence From a Systematic Review With Meta-Analysis

Frontiers in Oncology ◽

10.3389/fonc.2021.650488 ◽

2021 ◽

Vol 11 ◽

Author(s):

Xiaoli Hu ◽

Yang Liu ◽

Zhitong Bing ◽

Qian Ye ◽

Chengcheng Li

Keyword(s):

Breast Cancer ◽

Gene Expression ◽

Systematic Review ◽

Cancer Patients ◽

Poor Prognosis ◽

Data Extraction ◽

Meta Analysis ◽

Gene Expression Omnibus ◽

Breast Cancer Patients ◽

Node Metastases

Owing to metastases and drug resistance, the prognosis of breast cancer is still dismal. Therefore, it is necessary to find new prognostic markers to improve the efficacy of breast cancer treatment. Literature shows a controversy between moesin (MSN) expression and prognosis in breast cancer. Here, we aimed to conduct a systematic review and meta-analysis to evaluate the prognostic relationship between MSN and breast cancer. Literature retrieval was conducted in the following databases: PubMed, Web of Science, Embase, and Cochrane. Two reviewers independently performed the screening of studies and data extraction. The Gene Expression Omnibus (GEO) database including both breast cancer gene expression and follow-up datasets was selected to verify literature results. The R software was employed for the meta-analysis. A total of 9 articles with 3,039 patients and 16 datasets with 2,916 patients were ultimately included. Results indicated that there was a significant relationship between MSN and lymph node metastases (P < 0.05), and high MSN expression was associated with poor outcome of breast cancer patients (HR = 1.99; 95% CI 1.73–2.24). In summary, there is available evidence to support that high MSN expression has valuable importance for the poor prognosis in breast cancer patients.Systematic Review Registrationhttps://inplasy.com/inplasy-2020-8-0039/.

Download Full-text